CXCL13 and non-Hodgkin lymphoma: Both CXCL13 serum and saliva levels were significantly increased in high risk pSS patients for NHL development compared to those in low risk (median serum concentration: 95.31 pg/ml vs 44.57 pg/ml, p: 0.025; median saliva concentration 53.56 pg/ml vs 10.31 pg/ml in patients at high and low risk, respectively, p= 0.019), whereas CXCL13 saliva levels were marginally higher in patients with high disease activity (37.23 pg/ml vs 16.55 pg/ml in patients with ESSDAI score≥5 vs those with ESSDAI<5, p=0.057).